BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 28421294)

  • 1. A prospective comparison of intra-arterial chemotherapy combined with intravesical chemotherapy and intravesical chemotherapy alone after transurethral resection with a thulium laser in high-risk non-muscle invasive bladder cancer.
    Sun F; Zhao R; Zhu Y; Cui D; Wang X; Han B; Liang S; Liu H; Sun X; Zhao F; Xu D; Xia S
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1099-1107. PubMed ID: 28421294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the effects of intra-arterial chemotherapy combined with intravesical chemotherapy against intravesical chemotherapy alone after transurethral resection of bladder tumor in T1-staged Grade 3 bladder cancer.
    Huang B; Wang H; Lin H; Yao Z; Zheng J; Fan W; Qiu S; Chen L; Chen J
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):487-494. PubMed ID: 30539282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery.
    Chen J; Yao Z; Qiu S; Chen L; Wang Y; Yang J; Li J
    Cardiovasc Intervent Radiol; 2013 Dec; 36(6):1521-1526. PubMed ID: 23511989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor.
    Huang B; Huang G; Li W; Chen L; Mao X; Chen J
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1781-1788. PubMed ID: 33222014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intra-arterial chemotherapy combined with intravesical chemotherapy is effective in preventing recurrence in non-muscle invasive bladder cancer.
    Lian F; Chen W; Liu Y; Shen L; Fan W; Cui W; Zhao Y; Li J; Wang Y
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1625-1633. PubMed ID: 30900154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of immediate postoperative intravesical epirubicin instillation as an adjunct to standard adjuvant treatment in intermediate and high-risk non-muscle-invasive bladder cancer: A preliminary results of randomized controlled trial.
    Elsawy AA; El-Assmy AM; Bazeed MA; Ali-El-Dein B
    Urol Oncol; 2019 Mar; 37(3):179.e9-179.e18. PubMed ID: 30448030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of intra-arterial chemotherapy combined with intravesical chemotherapy in T1G3 bladder cancer when compared with intravesical chemotherapy alone after bladder-sparing surgery: a retrospective study.
    Huang B; Zheng J; Yao Z; Fan W; Qiu S; Chen L; Chen J
    World J Urol; 2019 May; 37(5):823-829. PubMed ID: 30191393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
    Ali-el-Dein B; el-Baz M; Aly AN; Shamaa S; Ashamallah A
    J Urol; 1997 Jul; 158(1):68-73; discussion 73-4. PubMed ID: 9186325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
    Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intra-arterial chemotherapy is reliable in preventing high-risk superficial bladder cancer from recurrence and progression.
    Chen MK; Qin ZK; Zhou FJ; Han H; Liu ZW; Li YH; Yao K; Hou GL; Ye YL; Zhang ZL; Tu H; Zhang XQ; Lu KS; Yang ZW
    J Chemother; 2009 Dec; 21(6):681-6. PubMed ID: 20071293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The intravesical recurrence after 3-day consecutive intravesical instillation of pirarubicine hydrochloride (THP) following transurethral resection of bladder tumor (TURBT) for non-muscle-invasive bladder cancer].
    Tochigi T; Sakurada Y; Aoki H; Kawamura S; Itou S; Satou I; Tateno H
    Nihon Hinyokika Gakkai Zasshi; 2012 Jul; 103(4):610-6. PubMed ID: 23120995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Intravesical Recurrence After Bladder-preserving Therapy for Muscle-invasive Bladder Cancer.
    Onozawa M; Miyanaga N; Hinotsu S; Miyazaki J; Oikawa T; Kimura T; Takaoka E; Kawai K; Shimazui T; Sakurai H; Nishiyama H; Akaza H
    Jpn J Clin Oncol; 2012 Sep; 42(9):825-30. PubMed ID: 22782963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study.
    Duchek M; Johansson R; Jahnson S; Mestad O; Hellström P; Hellsten S; Malmström PU;
    Eur Urol; 2010 Jan; 57(1):25-31. PubMed ID: 19819617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic overview of chemotherapy effects in urothelial bladder cancer.
    Nilsson S; Ragnhammar P; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):371-90. PubMed ID: 11441942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection.
    Mitsumori K; Tsuchiya N; Habuchi T; Li Z; Akao T; Ohyama C; Sato K; Kato T
    BJU Int; 2004 Aug; 94(3):317-21. PubMed ID: 15291859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intravesical instillation with epirubicin as a prophylactic treatment for superficial bladder cancer--using two different schedules].
    Segawa N; Nishida T; Takahara K; Nomi H; Azuma H; Katsuoka Y
    Hinyokika Kiyo; 2008 Nov; 54(11):711-6. PubMed ID: 19068724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of transurethral thulium laser en bloc resection combined with a single immediate postoperative intravesical instillation of pirarubicin in primary non-muscle-invasive bladder cancer.
    Xu S; Tan S; Wu T; Gu J; Xu L; Che X
    Lasers Med Sci; 2020 Oct; 35(8):1695-1701. PubMed ID: 31970565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value of European Organisation for Research and Treatment of Cancer score system for predication of immediate postoperative intravesical instillation of pirarubicin after transurethral resection of non-muscle invasive bladder cancer].
    Ding XL; Yang DL; Yan RP; Li ZP; Ye CW; He J; Yu L; He SC; Li HD
    Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):308-312. PubMed ID: 29730921
    [No Abstract]   [Full Text] [Related]  

  • 20. Intravesical instillation of epirubicin: effect on tumour recurrence in patients with dysplastic epithelium after transurethral resection of superficial bladder tumour.
    Igawa M; Urakami S; Shirakawa H; Shiina H; Ishibe T; Kadena H; Usui T; Kawanishi M
    Br J Urol; 1996 Mar; 77(3):358-62. PubMed ID: 8814838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.